Market Signal Briefing

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  September 24, 2025 to October 31, 2025

DEADLINE: April 13, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. UniQure's Pivotal Study design, including the comparison of the Pivotal Study to the ENROLL-HD data set, did not achieve full FDA approval. The Company understated the chances its BLA application with the FDA would face delays caused by the need for additional studies. Based on these facts, uniQure's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against F5, Inc. ("F5" or "the Company") (NASDAQ: FFIV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 28, 2024 and October 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before February 17, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. F5 touted the strength of its security and ability to fulfill customer needs. In reality, the Company suffered a security incident putting its customers and growth prospects at risk. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about F5, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Varonis Systems, Inc. ("Varonis" or "the Company") (NASDAQ: VRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 4, 2025 and October 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before March 9, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Varonis made extremely optimistic statements about its ability to convert its existing customers to its SaaS offering. The Company knew it was struggling to convince customers to switch to the new platform, reducing the opportunity for ARR growth. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Varonis, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

Q4: 2026-02-12 Earnings SummaryEPS of $0.04 beats by $0.01

 |

Revenue of

$203.08M

(-14.39% Y/Y)

beats by $3.92M

Himax Technologies, Inc. (HIMX) Q4 2025 Earnings Call February 12, 2026 8:00 AM EST

Company Participants

Karen Tiao - Head of IR/PR & Spokesperson
Jordan Wu - Co-Founder, President, CEO & Director

Conference Call Participants

Hsin Yeh - Morgan Stanley, Research Division

Presentation

Operator

Hello, ladies and gentlemen, welcome to Himax Technologies, Inc. Fourth Quarter and Fiscal Year of 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Ms. Karen Tiao, Head of IR/PR in Himax. Ms. Tiao, please go ahead.

Karen Tiao
Head of IR/PR & Spokesperson

Welcome, everyone. My name is Karen Tiao, Head of IR/PR at Himax. Joining me today are Jordan Wu, President and Chief Executive Officer; and Jessica Pan, Chief Financial Officer.

After the company's prepared comments, we have allocated time for questions in the Q&A section. If you have not yet received a copy of today's results release, please e-mail [email protected] or [email protected] or download a copy from Himax's website.

Before we begin the formal remarks, I would like to remind everyone that [Technical Difficulty] conference call, including statements regarding expected future financial results and industry growth, are forward-looking statements that involve a number of risks and uncertainties that could cause actual events or results to differ materially from those described in this conference call.

A list of risk factors can be found in the company's latest SEC filings, Form 20-F in the section entitled Risk Factors as may be amended. Except for the company's full year 2024 financials, which were provided in the company's 20-F and filed with SEC on April 2, 2025, the financial information included in this conference call is unaudited and consolidated and prepared in accordance with IFRS accounting.

Such financial information is

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p = 0.057) at Week 136, 4 weeks after the end of study treatment1.

Clinically meaningful results were observed with Vanrafia compared to placebo in eGFR change from baseline at the end of study treatment at Week 132, and in the prespecified exploratory group of patients additionally receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors1. At the end of treatment at Week 132, the eGFR change from baseline compared to placebo was 2.59 ml/min/1.73 m2 (nominal 2- sided p = 0.039)1.

“Progressive and complex diseases such as IgAN present an urgent need for medicines that can target the different drivers of the disease. Vanrafia can be seamlessly integrated into patients’ existing treatment plans, with a consistent safety profile,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal & Metabolic Development Unit, Novartis. “We are pleased with today’s Phase III ALIGN results, which add to the growing evidence of Vanrafia as a potential foundational therapy to slow kidney function decline.”

ALIGN provides the longest follow-up period in pivotal Phase III studies for IgAN3. Safety was consistent with previous findings1.

Alongside Vanrafia, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Fabhalta® (iptacopan) and investigational compound zigakibart.

About IgAN
IgAN is a progressive autoimmune kidney disease with approximately 25 per million people newly diagnosed worldwide each year4. IgAN is highly debilitating as it leads to glomerular inflammation (when the small filters in the kidneys are inflamed), proteinuria (excess protein in urine), and a gradual decline in eGFR5. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or kidney transplantation as part of long-term disease management5-7.

Furthermore, people living with IgAN often face mental, social, and economic challenges5-8. Supportive care has not addressed the underlying causes of the disease and often fails to slow disease progression, reinforcing the need for more targeted therapies for IgAN4-9.

About Vanrafia® (atrasentan)
Vanrafia (atrasentan) is a potent and highly selective endothelin A (ETA) receptor antagonist, which is part of the endothelin system, a key system involved in the progression of IgAN10-13.

Vanrafia is the first and only selective ETA receptor antagonist approved for primary IgAN, a once-daily, oral treatment and can be seamlessly added to, or used alongside, existing supportive care (e.g. renin-angiotensin system (RAS) inhibitor with or without SGLT2 inhibitor) without the need for titration2. Vanrafia does not require a Risk Evaluation and Mitigation Strategy (REMS) program. Because some endothelin receptor antagonists have caused elevations of aminotransferases, hepatotoxicity, and liver failure, clinicians should obtain liver enzyme testing before initiating Vanrafia and during treatment when clinically indicated. Vanrafia may cause serious birth defects2.

About ALIGN
The ALIGN study (NCT04573478) is a global, randomized, multicenter, double-blind, placebo-controlled Phase III clinical trial comparing the efficacy and safety of Vanrafia versus placebo in patients with IgAN at risk of progressive loss of kidney function1-3. In total, 340 patients with biopsy-proven IgAN with baseline total proteinuria ≥1 g/day despite optimized RAS inhibitor treatment were randomized to receive once-daily, oral Vanrafia (0.75 mg) or placebo for approximately 132 weeks1,11. Patients continue receiving a maximally tolerated and stable dose of a RAS inhibitor as supportive care1,11. An additional cohort of 64 patients receiving an SGLT2 inhibitor in addition to RAS inhibitor for at least 12 weeks was also enrolled1,11. The primary efficacy endpoint for the interim analysis (in 270 patients) was change in proteinuria, as measured by 24-hour urine protein-to-creatinine ratio (UPCR) from baseline to 36 weeks1,3,11. The key secondary endpoint for the final analysis is the change from baseline to 136 weeks in kidney function as measured by eGFR. Other secondary efficacy endpoints as well as safety and tolerability are also assessed1-3.

Novartis commitment to kidney diseases 
Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.

Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis, and get patients the right care, sooner.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  April 1, 2024 to December 16, 2025
DEADLINE: March 16, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Vistagen misled investors about the results of its PALISADE-2 trial of fasedienol. The Company created the false impression that its drug candidate would enjoy a successful Phase 3 trial. Based on these facts, Vistagen's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
 Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Ardent Health, Inc. ("Ardent " or "the Company") (NYSE: ARDT ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of ARDT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  July 18, 2024 to November 12, 2025

DEADLINE: March 9, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Ardent utilized a 180-day cliff on accounts receivable so it could report higher amounts of accounts receivable and delay recognizing losses. Based on these facts, Ardent's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against BellRing Brands, Inc. ("BellRing" or "the Company") (NYSE: BRBR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of BRBR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  November 19, 2024 to August 4, 2025
DEADLINE: March 23, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. BellRing misled the market by claiming it enjoyed strong customer demand and a strong competitive position in the market. In fact, its sales were driven by customers stockpiling inventory. Based on these facts, BellRing's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
 Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Beyond Meat, Inc. ("Beyond Meat" or "the Company") (NASDAQ: BYND) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 27, 2025 and November 11, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before March 24, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Beyond Meat carried a higher book value for long-lived assets than their fair value. The Company was likely to be required to record a non-cash impairment charge due to this issue. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Beyond Meat, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

A great quarter wasn't enough to save Monday.com from a 25% plunge. The real culprit might surprise you.

Shares of Monday.com (MNDY +0.74%) plunged this week, according to data from S&P Global Market Intelligence. From last Friday's market close to the closing bell on Feb. 12, the stock price fell 25%.

True to its name, Monday.com reported earnings early Monday morning. The report itself was better than expected, but the company disappointed investors with modest guidance for the next fiscal year.

Today's Change

(

0.74

%) $

0.54

Current Price

$

73.63

Great quarter, scary guidance withdrawal Let's start with the basic financials. Monday.com's revenue rose 25% year over year, landing at $333.9 million. Adjusted earnings fell from $1.08 to $1.04 per diluted share. In both cases, Wall Street expected something worse. The analyst consensus pointed to earnings near $0.92 per share on revenue in the neighborhood of $329.5 million.

The results also exceeded the midpoints of Monday.com's guidance ranges, which aimed at revenue around $329 million and significantly weaker operating income.

However, management withdrew its existing 2027 guidance due to currency exchange headwinds and "the evolving nature of the AI landscape," according to conference call comments. Many investors saw this canceled guidance as a sign that AI agents are stealing Monday.com's business in the project management and online collaboration markets. The stock closed 20.1% lower that day and hovered around that lower level for the rest of the week.

Image source: Getty Images.

Is Monday.com sandbagging again? This company has a history of setting modest guidance targets and hitting them out of the park with stronger real-world performance. Revoking longer-term growth goals would take the lowballing to a new level, but management projects roughly 18% revenue growth and 28% higher adjusted operating profits in 2026. Those are lofty growth targets.

And Monday.com is taking action against the potential AI challenge. The company offers its own AI agent platform, letting clients integrate multi-step AI tools in their Work OS applications. In the end, AI could be more of an opportunity than a threat for this innovative company.

I think the resulting price drop was an overreaction. If you don't own any Monday.com stock yet, this could be a good time to get started.

Anders Bylund has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Monday.com. The Motley Fool has a disclosure policy.

SummaryCompaniesGE Aerospace targets more repairs via automation in SingaporeRobots learn blade-work once done by handBacklogs may ease, but shortages persistSINGAPORE, Feb 13 (Reuters) - GE Aerospace (GE.N), opens new tab technician Suresh Sinnaiyan has spent more than a decade repairing jet‑engine compressor blades by guiding them across a sanding belt with practised precision.

Now, at the aerospace giant's new automation lab in Singapore, he is teaching a robot to do the same job.

Stay up to date with the latest news, trends and innovations that are driving the global automotive industry with the Reuters Auto File newsletter. Sign up here.

The switch is part of GE's push to prepare the next wave of industrial development and ease one of aviation's biggest bottlenecks: overloaded repair shops and scarce parts.

Unexpected wear and tear in the latest generation of jet engines across the industry has idled many jets and led airlines to keep older jets flying longer, stretching maintenance lines into months as engines wait their turn in repair queues.

That pressure has turned into a public fight. Airlines have complained that engine makers are benefiting from shortages by raising prices, while manufacturers say they are pouring money into expanding support after shouldering huge development costs.

Tony Fernandes, the co-founder of Malaysian low-cost airline AirAsia, put it candidly: "They have got to remember airlines are their future and treat us as partners," he told Reuters, referring to the industry overall.

SINGAPORE AS THE PRESSURE VALVEGE says Singapore is a key piece of its answer.

The company's 2,000-employee repair hub is being upgraded with more automation, digital tools and AI as part of a plan that GE has said could total up to $300 million in investment.

The company aims to lift repair volume in Singapore by 33% without expanding the site's footprint — by reorganising work, reshaping floor space and automating tasks where it is efficient.

The plant is at the forefront of efforts to roll out "Flight Deck," GE's version of the "Lean" manufacturing recipe of continuous improvement and eliminating waste pioneered by Japanese carmakers and championed by CEO Larry Culp.

"It's not about sprinting at quarter's end to make a Wall Street guide. It is making every hour and every day count," Culp told Reuters in an interview.

GE and rivals such as Pratt & Whitney (RTX.N), opens new tab have been trying to balance feeding new-airplane assembly lines with engines and parts while keeping the existing fleet flying.

Repairing more used parts can ease pressure by safely reducing the need to replace worn components with newly manufactured ones — leaving more available for new engines.

And GE says repairs can halve the time needed for key processes as well as halve the cost to airlines.

FASTER TURNS, TIGHTER FLOOR SPACE"Repair can really improve turnaround time … the less time the engine is off the wing, the better," Iain Rodger, head of GE Aerospace Component Repair Singapore, told Reuters during a visit to the facility.

One example is a reorganised repair area overhauling used and scorched CFM56 turbine nozzles — parts that endure extreme heat inside one of the world's most widely used engines.

Workers say turnaround time there has improved since 2021, when it was 40 days, and GE is targeting 21 days by 2028.

The area is giving up roughly a third of its floor space to prepare for the next challenge: developing repair capability for newer LEAP engines that are beginning to enter overhaul cycles.

Without approved repairs, airlines may need to replace worn parts with new ones, which are typically more expensive and in limited supply.

"Now we can see problems and identify where issues are," said Nozzles Business Leader Han Hui Min of the new layout.

TEACHING ROBOTS THE HUMAN TOUCHThe most compelling work is also among the hardest to automate: repairs that depend on a technician's touch.

Take those compressor blades from a CFM56 engine.

As air rushes into the core of the engine, spinning blades squeeze it to build pressure. Over years of use, blade tips deform and must be restored in a process called blending — reshaping the metal so it meets tight tolerances.

"It's really hard to do. (Until now) it is 100% manual," said Sinnaiyan. Each blade has to be filed to within a few thousandths of an inch, relying on eye, feel and coordination.

GE's bet is that if it can capture that skill in a repeatable robotic process, it can reduce dependence on scarce specialised labour and increase throughput at lower cost.

Analysts note that engine makers earn some of their biggest profits from servicing used parts and from licensing certain repairs to other shops in return for lucrative royalties.

That means the process for each repair is considered the secret sauce for an increasingly crucial part of the business.

Even so, scaling repairs has limits. Work must follow approved procedures and strict quality controls.

And a slowdown in new plane production which boosted the demand for old jets - and in turn demand for repairs - is coming towards an end, Agency Partners analyst Nick Cunningham said.

If GE's changes in Singapore deliver, they could help the industry work through its bottlenecks and ease fares.

But airline executives and others have cautioned that the underlying supply squeeze is unlikely to vanish quickly.

"It is about moving away from fire fighting and heroics to a different type of preferred performance," Culp said.

Reporting by Tim Hepher in Singapore and Rajesh Kumar Singh in Chicago; Editing by Joe Brock and Matthew Lewis

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Rajesh Kumar Singh is the U.S. Aviation Correspondent at Reuters, based in Chicago, where he reports on airlines, aircraft manufacturers, and regulatory developments that shape the global aviation industry. Prior to this role, he covered U.S. manufacturing and trade policy, including the U.S.–China trade wars, where his work delved into the disruption facing American businesses and the strategic responses of major corporations. He began his career with Reuters in India, where he reported on a wide range of issues covering the country's economic complexities—from its recovery after the global financial crisis to the challenges of inflation and governance.

Roku, Inc. (ROKU) Q4 2025 Earnings Call Transcript

Summary: For Meta (META) and Microsoft (MSFT), it has indeed been a tale of two tech giants as of late.

Shares in Norwegian Cruise Line have underperformed its peer set significantly over the past year. The discount in valuation to both its peers and to the broader market indexes presents an attractive buying opportunity, in my view. I see the company benefitting from a strong wave season through 2026 and beyond.

Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call February 12, 2026 4:30 PM EST

Company Participants

Joseph Sardano - Co-Founder, Chairman & CEO
Michael Sardano - President, Chief Commercial Officer, General Counsel, Corporate Secretary & Director
Javier Rampolla - Chief Financial Officer

Conference Call Participants

Tirth Patel - Lippert/Heilshorn & Associates, Inc.
Anthony Vendetti - Maxim Group LLC, Research Division
Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division

Presentation

Operator

Good afternoon, and welcome to the Sensus Healthcare Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Tirth Patel with Alliance Advisors IR. Please go ahead.

Tirth Patel
Lippert/Heilshorn & Associates, Inc.

Good afternoon. This is Tirth Patel with Alliance Advisors IR. Thank you all for joining today's call to discuss Sensus Healthcare's Fourth Quarter and Full year 2025 financial results.

Joining me from Sensus are Joe Sardano, Chairman and Chief Executive Officer; Michael Sardano, President, Chief Commercial Officer and General Counsel; and Javier Rampolla, Chief Financial Officer.

As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends or anticipates and other similar expressions will, should or may occur in the future are forward-looking statements.

The forward-looking statements are management's beliefs based upon currently available information as of the date of this conference call, February 12, 2026. Sensus Healthcare undertakes no obligation to revise or update any forward-looking statements, except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K, 10-Q and other SEC filings.

During today's call, references will be

One of Wall Street's darlings of the last few years is getting hammered.

Let's just cut to the chase. Palantir (PLTR 4.83%) stock still looks overvalued, and I'm still not buying.

But why? After all, the artificial intelligence data and analytics platform company reported extraordinary fourth-quarter results, featuring a 70% year-over-year increase in revenue. Even more, the midpoint of the company's guidance implies even faster revenue growth in the first quarter of 2026. And what is Palantir management saying? The company is "in the middle of a tectonic shift" in the adoption of its software.

So, why wouldn't I like a stock like this?

The problem boils down to valuation. The stock is simply priced for perfection, leaving essentially no room for error -- and not even enough room for a natural deceleration in the company's growth over the next 5 years.

Image source: Getty Images.

Before we dive into more details, let me make one more thing clear: saying the stock is not attractive is not a critique of the management team or the business itself. This is a great business, and the company is executing exceptionally well. But sometimes when companies are at the center of the market's most exciting investment theme, the best-performing companies can see their stocks soar a bit too far. This is what happened to Palantir. Even after the growth stock's recent pullback, shares are up more than 1,600% over the past three years.

Accelerating growth Palantir's revenue isn't just growing fast; it's accelerating. The year-over-year revenue growth rates for Palantir in the first, second, third, and fourth quarters of 2025 were 39%, 48%, 63%, and 70%, respectively. With a top-line trend like this, it's easy to see why investors love this business.

Making the company's recent performance even more impressive, Palantir's profitability has inflected recently. Palantir's net income in 2025, for instance, rose more than 250% year over year to $1.625 billion.

But what if growth slows? The problem, however, is that the stock's price-to-earnings ratio of more than 200 as of this writing prices in more strong growth like this for years to come.

To provide more perspective on the stock's valuation, consider its market capitalization. As of this writing, Palantir commands a market capitalization of more than $306 billion despite trailing-12-month sales and net income of approximately $4.5 billion and $1.6 billion, respectively. The gap between Palantir's market capitalization and its underlying fundamentals is a chasm.

Today's Change

(

-4.83

%) $

-6.55

Current Price

$

129.13

Even when you take the stock's price as a multiple of analysts' consensus earnings-per-share forecast over the next 12 months, shares are expensive. The stock's forward price-to-earnings ratio is about 110 as of this writing.

A valuation like this could be a disaster waiting to happen if the company's growth starts to slow. And while Palantir's first-quarter guidance suggests a slowdown won't occur anytime soon, it could be on the horizon. Just look at Palantir's decelerating growth rate in its total contract value (TCV), or the potential lifetime value of its customer contracts. The company closed $4.3 billion worth of TCV in Q4. This was up 138% year over year -- a slowdown from 151% growth in Q3.

Of course, it's not like this 138% growth in closed TCV during Q4 is poor performance. Management should be extremely proud of this performance. But if closed TCV continues to decelerate throughout 2026, it could signal slower revenue growth.

Overall, Palantir's business continues to fire on all cylinders. But there's a price for everything, and the price for Palantir stock arguably remains egregious. While it's always possible that Palantir delivers the extraordinary growth required to justify its valuation and still reward shareholders with attractive returns from here, I don't think the risk is worth it at the stock's current price.

The Magnum Ice Cream Company N.V. (MICC) Q4 2025 Earnings Call February 12, 2026 5:00 AM EST

Company Participants

Michele Negen
Peter Kulve - CEO & Executive Director
Abhijit Bhattacharya - CFO & Executive Director

Conference Call Participants

Warren Ackerman - Barclays Bank PLC, Research Division
Celine Pannuti - JPMorgan Chase & Co, Research Division
Jeff Stent - BNP Paribas, Research Division
David Roux - Morgan Stanley, Research Division
Karel Zoete - Kepler Cheuvreux, Research Division
Robert Jan Vos - ODDO BHF Corporate & Markets, Research Division
Bingqing Zhu - Rothschild & Co Redburn, Research Division
David Hayes - Jefferies LLC, Research Division
Antoine Prevot - BofA Securities, Research Division
Jeremy Kincaid - Kempen & Co. N.V., Research Division
Guillaume Gerard Delmas - UBS Investment Bank, Research Division

Presentation

Operator

Good morning, and welcome to The Magnum Ice Cream Company Webcast for the Full Year 2025 Results. My name is Heidi, and I will be your operator for today's call.

Before we begin, please note that today's presentation is being recorded. [Operator Instructions]

With that, I am pleased to turn the call over to Michele Negen. Michele, please go ahead.

Michele Negen

Good morning, everyone. Welcome to The Magnum Ice Cream Company's First Full Year 2025 Results Webcast. My name is Michele Negen, Head of Investor Relations, and I'm here today with our CEO, Peter ter Kulve; and our CFO, Abhijit Bhattacharya.

The press release and investor presentation were published on our Investor Relations website this morning. The replay and full transcript of this webcast will be made available after the call as well.

Before we start, I want to draw your attention to our cautionary statement on the screen. You will also find this statement in the presentation published on the website.

In a moment, Peter will talk you through the key elements of our performance in 2025 and

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Phoenix Education Partners, Inc. (NYSE: PXED) resulting from allegations that Phoenix Education may have issued materially misleading business information to the investing public.

So What: If you purchased Phoenix Education securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=50770 mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On January 3, 2026, Fox News published an article entitled "University of Phoenix data breach hits 3.5M people." The story stated that the "University of Phoenix has confirmed a major data breach affecting nearly 3.5 million people. The incident traces back to August when attackers accessed the university's network and quietly stole sensitive information."

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P.A.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BATRA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryCompaniesDeutsche Bank Private Bank taps more bankers for emerging markets franchiseClients seeking diversification, opening more accounts in EuropeBank aims to capitalise on rising interest in Lombard loansSINGAPORE, Feb 13 (Reuters) - Deutsche Bank (DBKGn.DE), opens new tab plans to add up to 50 relationship managers in its emerging markets private banking unit this year, said a senior executive, as the European lender seeks to bolster its wealth footprint in the Gulf region and North Asia.

Marco Pagliara, head of emerging markets at Deutsche Bank Private Bank, told Reuters that "selective hiring" would also continue in 2027 and 2028, without giving specific targets or disclosing the number of relationship managers it has by region.

The Week in Breakingviews newsletter offers insights and ideas from Reuters' global financial commentary team. Sign up here.

The hiring spree is part of the private bank's aim to grow its emerging markets front office headcount by 50% over the next three years. A large number of the 250 bankers it aims to hire under a previously announced plan are set to be in the franchise.

CAPTURING GROWING GLOBAL WEALTHThe move comes as global banks have been ramping up their private banking offerings in recent years, especially in the fast-growing regions of Asia and the Middle East, to tap into the expanding population of millionaires and billionaires.

Global financial wealth reached an all-time high of $305 trillion in 2024, according to Boston Consulting Group's Global Wealth Report 2025.

Diversification, including where investors hold assets and how they allocate capital, has been a growing theme among the bank's wealthy clients, Pagliara said, amid rising global market volatility.

For instance, clients who previously held assets in Singapore or Hong Kong are now more likely to use other wealth centres as well, like Switzerland, Luxembourg and the UK, he said, as allocations to Europe-domiciled investments increase.

Switzerland will be another focus of the private bank's headcount expansion, Pagliara added.

The trend is in line with a push from money managers to invest in a broader range of asset classes across markets, particularly away from the United States, as geopolitical ructions and unpredictable policymaking weigh on sentiment.

"This diversification not only reflects (ultra-high-net-worth) family aspirations for global assets like real estate, it also reflects the clients' desire to diversify assets geographically to mitigate geopolitical risk," Pagliara said.

GROWING APPETITE FOR LEVERAGELombard lending - where private banking clients borrow against the value of their investment portfolios - is another area where the private bank is aiming to double down amid growing interest.

"Right now, I'm seeing more clients using the dry powder they've got," Frankfurt-headquartered Deutsche Bank Private Bank's global head of wealth management and business lending, Adam Russ, said in a separate interview.

"It's not a case of clients aggressively leveraging, but they are just taking leverage up a tick."

According to a 2024 report by Deloitte, Lombard lending, which helps private banks expand their assets under management, has been one of the fastest growing credit products since 2018, with a global market size of around $4.3 trillion.

"There's a lot of pent-up supply that can be used if people feel real conviction around certain trades, which is good, you know, being in a market like we're in right now," said Russ.

"Lombard lending is becoming more and more of a focus for us."

Reporting by Rae Wee; Editing by Sumeet Chatterjee and Kevin Buckland

Our Standards: The Thomson Reuters Trust Principles., opens new tab

SHANGHAI--(BUSINESS WIRE)--As Chinese communities around the world gear up to celebrate the Chinese New Year, China Eastern Airlines (CEA) has launched a special in-flight Wi-Fi upgrade for the Chinese New Year's Eve, offering passengers an immersive, real-time celebration experience at cruising altitude.

From 12:00 noon on Feb. 16 (Chinese New Year's Eve), Beijing Time, to 1:00 a.m. the following day, all widebody flights operated by CEA and Shanghai Airlines will offer complimentary high-speed in-flight Wi-Fi. Passengers can share festive moments in real time, stream Spring Festival galas, and celebrate the Chinese New Year alongside friends and family on the ground.

On Chinese New Year's Eve, nearly 200 widebody flights operated by CEA will connect 29 countries and regions across five continents, serving close to 50,000 passengers.

Starting at 1:00 a.m. on Feb. 17, the first day of the first month in the traditional Chinese calendar, passengers in all cabins on widebody flights between the Chinese mainland and Australia, New Zealand, 10 Southeast Asian countries—including Singapore, Malaysia, and Thailand—as well as China's Hong Kong, Macao and Taiwan, will be able to enjoy complimentary in-flight Wi‑Fi.

Recognized as a UNESCO Intangible Cultural Heritage, Chinese New Year serves as a bridge connecting people across the world.

With this comprehensive Wi-Fi upgrade, CEA aims to leverage technology to enhance passengers' travel experience during the holiday season, offering safer, more enjoyable and better-connected journeys and sharing the joy of the Chinese New Year with people around the globe, according to the airline.

📊
No votes yet – Be the first to vote

Robinhood and eToro got hammered Thursday. Bitcoin’s brutal drop to $63,500 dragged both trading platforms down hard, with Robinhood closing at $75.67 after losing nearly 10% in a single session.

That’s eight straight days of losses for Robinhood, wiping the stock back to June 2025 levels and erasing most gains from the late-2025 crypto boom. The pain spread across crypto-linked stocks as Bitcoin suffered its worst single-day beating in over a year, plunging more than 13% and hitting lows not seen since October 2024. eToro didn’t fare much better, dropping roughly 7% to close below $26.54. The trading platform went public on Nasdaq in May 2025 at $69 but has now lost over 60% of its value since that debut.

Bitcoin’s crash was pretty brutal.

The entire crypto market cap fell 6.4% in 24 hours to $2.49 trillion, with most of the top 100 digital assets bleeding red. Bitcoin’s now down 44% from its October peak, erasing over $800 billion in market value. Coinbase, the biggest U.S. crypto exchange, got crushed too, falling over 13% to around $152.44 for its eighth straight losing session.

The problem for these platforms is simple – they’re basically crypto plays in disguise. eToro’s revenue came 91% from digital assets in Q2 2025, making it extremely vulnerable to market swings. In 2024, crypto made up nearly 40% of eToro’s $931 million commission revenue, but that number bounces around wildly with Bitcoin’s price.

Arkadiusz Jóźwiak, a crypto analyst, put it bluntly: “Investors see shares of companies like eToro and Robinhood as indirect exposure to cryptocurrencies.”

He’s right. Their financial results are tied directly to crypto market performance, creating massive volatility in their stock prices. Robinhood’s more diversified than eToro but still faces serious crypto exposure. In Q3 2025, crypto revenue hit $268 million, about 20% of total revenue and a 339% year-over-year jump. But retail buying activity has slowed since late October’s surge, raising questions about whether trading volumes can stay high.

Both companies rode the 2024 digital asset wave hard. eToro’s commission revenue jumped 48% year-over-year, with Q4 2024 contributing big gains as Bitcoin surged. Net profit soared to $192 million from $15.3 million in 2023, driven almost entirely by crypto trading activity. More on this topic: Bitcoin ETF Inflows Reverse with 6.

Robinhood’s Q4 2024 cryptocurrency revenue of $358 million was up 700% year-over-year.

That number actually beat options trading revenue for the first time ever. The company reported total revenue of $2.95 billion for 2024, with crypto accounting for 21% of the total. Those gains look pretty shaky now with Bitcoin crashing and retail traders getting spooked by the volatility.

“When Bitcoin rises, everyone is happy and shares rise, but when it falls, sentiment changes,” Jóźwiak said. “If Bitcoin continues to fall, Robinhood and eToro may follow.” The analyst didn’t specify exact price targets, but the correlation seems pretty clear based on recent trading patterns.

The crypto crash hit other major players too. Binance reported trading volumes down over 10% compared to last month, reflecting broader caution among retail investors who are getting nervous about the wild price swings. Galaxy Digital saw its shares drop 15% to $9.87 on February 3, with CEO Mike Novogratz acknowledging the tough environment while maintaining long-term confidence in digital assets.

Grayscale’s Bitcoin Trust discount widened to 25% as of Thursday. This follows earlier reporting on FBI Joins Hunt for Nancy Guthrie.

That signals serious investor doubt, with the trust’s shares trading way below Bitcoin’s actual market price. MicroStrategy, which holds tons of Bitcoin, fell 12% to $210 on February 5 as its aggressive crypto strategy made the stock extremely sensitive to Bitcoin moves. Tesla dropped 5% to $198 the same day, partly due to its own Bitcoin holdings making the stock vulnerable to crypto volatility.

Square fell 8% to $125 despite CEO Jack Dorsey’s continued Bitcoin support and the company’s integration of crypto into Cash App. The SEC announced a review of recent market activity on February 4, including the sharp crypto price movements, though no immediate regulatory changes were indicated.

Kraken bucked the trend slightly, reporting higher trading volumes despite falling prices. CEO Jesse Powell noted that volatility actually drove more activity on their platform, though he didn’t provide specific numbers. Neither Robinhood nor eToro provided additional comments about their stock performance or crypto exposure strategies.

The regulatory environment adds another layer of uncertainty for crypto-focused trading platforms. The SEC’s ongoing scrutiny of digital asset operations has already forced several exchanges to modify their offerings, with Coinbase paying $100 million in fines last year for unregistered securities violations. European regulators under MiCA (Markets in Crypto-Assets) rules are implementing stricter compliance requirements that could impact eToro’s operations across EU markets, potentially increasing operational costs by an estimated 15-20% according to industry analysts.

Meanwhile, the broader fintech sector is watching these developments closely. Charles Schwab reported a 23% increase in crypto-related customer inquiries during January 2025, suggesting retail interest remains strong despite the volatility. Interactive Brokers expanded its crypto offerings in December 2024, adding support for 15 new digital assets and reporting $45 million in crypto-related revenue for Q4. Fidelity’s digital asset arm managed $8.2 billion in crypto investments as of January 2025, up from $6.1 billion six months earlier. These traditional brokers are positioning themselves to capture market share if platforms like Robinhood and eToro continue struggling with crypto dependency issues.

Post Views: 14

Bitcoin's seemingly random tumble doesn't bode well for the crypto sector's near term.

The frightening Feb. 5 air pocket in crypto was a reminder that bad headlines aren't the only thing that can cause crypto markets to absolutely crater. While it's still unclear what sparked the sell-off, it was nonetheless a remedial lesson for many investors that Bitcoin (BTC 1.61%) still sets the tone for the sector. That's even the case when leading assets like Ethereum (ETH 0.60%) and Solana (SOL 2.06%) have their own stories, which (in theory) shouldn't be affected by anything that happens to Bitcoin.

The next few moves in this market will probably test your patience. Here's what Bitcoin's big stumble is going to do for other crypto majors.

Image source: Getty Images.

Bitcoin is the moon, and other coins are the tide In the run-up to the collapse, the mood was quite ugly across the board, which paved the way for Bitcoin to crash by 14% on Feb. 5 before rebounding somewhat in the following days. From Jan. 30 to Feb. 6, Bitcoin fell about 25%, taking Solana down by 33% and Ethereum down by 35% along with it.

It's a common story that when investors' risk appetite breaks, for whatever reason, assets can become more correlated very quickly. That happens because crypto is still treated as a single risk bucket during periods of stress. People sell what they have on hand, not just what they dislike, and they often sell because they're being forced to meet margin calls or other institutional financial constraints.

Today's Change

(

-1.61

%) $

-1089.27

Current Price

$

66447.00

If Bitcoin keeps whipping around, you should assume that the rest of the market will remain panicked and flighty, even if no new bearish (or bullish) news develops with Ethereum or Solana. Still, there are a couple of things about those coins that are likely to be relevant over the next few months.

Ethereum and Solana have their own battles to win Ethereum has a real tailwind in scaling that's starting to develop. Its roadmap has moved toward creating the technical groundwork for dramatically lowering its transaction costs while also increasing its chain performance and throughput.

But Ethereum also has a headwind. Improving its scaling also works against its fee model, as lower costs imply fewer coins burned, and thus less upward pressure on prices for holders. It's unclear how, or if, that issue will get resolved.

Today's Change

(

-0.60

%) $

-11.82

Current Price

$

1951.70

In contrast, Solana's pitch remains high speeds and low costs, and it has been pushing hard on its chain's reliability and its user diversity. A major new validator client going live on its mainnet in December is part of that effort, and it might attract more capital to the chain this year.

But presently, Solana's big risk is demand quality.

Today's Change

(

-2.06

%) $

-1.66

Current Price

$

79.01

If the chain's activity mix leans too heavily on cyclical pockets of speculation, such as projects intended for gambling on meme coins, it can underperform for longer after a sectorwide drawdown. In other words, investors might stop paying up for growth until the source of the growth looks durable enough to last, which speculation-oriented projects simply cannot deliver.

So right now's a very risky time to be buying crypto. But the picture is likely to be a bit less gloomy in a few weeks or a couple of months, when the dust has settled.

Ethereum continues to trade below the critical $2,000 level, reflecting persistent market pressure as traders await a clearer directional catalyst. The inability to reclaim this psychological threshold has kept sentiment cautious, with volatility elevated and liquidity conditions still uncertain. While price action has stabilized somewhat after recent declines, the broader structure suggests the market is preparing for a decisive move that could define Ethereum’s short-term trajectory.

A recent CryptoQuant report provides important context, indicating that the Ethereum market has undergone one of its most prolonged periods of stress since mid-2021. According to the data, the 7-day simple moving average of long liquidations on Binance climbed to roughly 9,000 ETH on February 6, 2026. Because this figure represents a smoothed weekly average rather than a single-day spike, it signals sustained pressure rather than a brief liquidation cascade.

Ethereum Long Liquidations | Source: CryptoQuant This pattern implies that leveraged long positions have been unwound gradually over several days. Pointing to persistent deleveraging rather than a sudden capitulation event. Historically, extended liquidation phases can reset market leverage and reduce speculative excess, though they also tend to coincide with fragile sentiment. Whether this process ultimately stabilizes Ethereum or leads to further downside remains dependent on liquidity conditions and broader market demand.

Sustained Liquidations Signal Derivatives Market Reset The CryptoQuant report further notes that Ethereum’s decline from the $3,000 region to the $2,000 range did not trigger any capitulation events. Instead, the market experienced a prolonged sequence of margin calls, with leveraged long positions gradually unwound over several consecutive days. This pattern reflects persistent stress in the derivatives market rather than a short-lived liquidation cascade. Indicating that traders faced sustained pressure as the price trended lower.

From a historical standpoint, the intensity and duration of this liquidation phase appear to exceed those recorded during major capitulation periods of the 2022 bear market. Such extended liquidation activity typically signals a broad deleveraging cycle, where excessive speculative positioning is systematically cleared. This process often reshapes market structure by reducing leverage-driven volatility and restoring a more balanced risk environment.

The implication is that Ethereum may have already undergone a significant leverage reset in recent weeks. Persistently elevated liquidation averages can sometimes precede seller exhaustion. Weaker market participants exit positions, and forced selling pressure gradually subsides.

The durability of any recovery will likely depend on renewed spot demand and macro liquidity conditions. Also, investor confidence must return following this extended period of derivatives-driven stress.

Ethereum Tests Long-Term Support: Weekly Structure Weakens Ethereum’s weekly chart shows increasing structural pressure after the loss of the $2,000 level, a threshold that previously acted as both psychological support and a key technical pivot. The recent breakdown places ETH below major trend-defining moving averages, suggesting weakening bullish momentum and a shift toward a more defensive market environment.

ETH testing critical demand | Source: ETHUSDT chart on TradingView Price action reflects a clear rejection from the $3,000 region earlier in the cycle. Followed by a sequence of lower highs that typically characterizes transitional or corrective phases. The latest decline also coincides with rising trading volume, often associated with distribution or leveraged position unwinding rather than organic accumulation. This dynamic reinforces the perception of ongoing market stress rather than stabilization.

From a structural standpoint, the next meaningful support area appears around the mid-$1,500 to $1,700 zone, where previous consolidation and demand emerged in earlier phases. Holding above this range would help preserve the broader long-term bullish framework, even amid current weakness. A sustained break below it, however, could shift sentiment toward a deeper corrective cycle.

Ethereum remains sensitive to macro liquidity conditions, derivatives positioning, and overall crypto market sentiment, with recovery dependent on renewed spot demand and stabilization above key technical levels.

Featured image from ChatGPT, chart from TradingView.com 

Aave Labs has floated a new plan that could send all product revenue to the Aave community.

Summary

Aave Labs proposed sending 100% of product revenue to Aave DAO. The plan covers fees from Aave v3, v4, aave.com, and future products. In return, Labs is seeking funding from the DAO to support operations. Aave Labs has unveiled a new governance proposal that could reshape how revenue flows within the Aave ecosystem. In a non-binding “temperature check” posted on Feb. 12, the company asked the community whether it would support sending all product-related revenue directly to the DAO.

The proposal, titled “Aave Will Win,” suggests that income from Aave-branded products should be re-directed to the protocol’s governing body, Aave DAO, rather than remaining with the development team.

A plan to redirect revenue to the DAO Under the proposal, Aave Labs wants 100% of revenue from its products to flow into the DAO treasury. This includes swap fees from Aave v3 and the upcoming v4, earnings from the official aave.com interface, and income from future ventures such as the Aave Card and possible ETF-related products.

If approved, this structure would place token holders at the center of value creation. Supporters say it could reduce concerns about “value leakage,” where parts of the ecosystem generate income without benefiting the DAO.

The plan also includes creating a new foundation to hold Aave’s trademarks and intellectual property. This entity would manage the brand on behalf of the community, rather than leaving those assets under company control.

At the same time, Aave Labs is asking for long-term financial support from the DAO. The proposal requests $25 million in stablecoins, 75,000 Aave (AAVE) tokens, and additional grants tied to specific products. 

A more open budget system would allocate these funds to operations, marketing, and development. Aave founder Stani Kulechov said the framework is designed to establish a “token-first” relationship between the DAO and its primary developer. 

Community reaction and open questions Aave community’s response to the proposal has been mixed. Since protocol success directly benefits AAVE holders, some token holders view it as a significant step toward greater alignment. They argue that the model’s value returns are more obvious and that it resembles a shareholder structure in traditional finance. 

Some are more cautious. Critics question whether Aave Labs is actually giving up economic power and point to the size of the funding request. Marc Zeller and other commentators have raised concerns that the upfront payments could offset much of the revenue being redirected.

The dispute comes after months of conflict over control and ownership. After Aave Labs re-directed interface fees away from the DAO in late 2025, they faced major criticism. Following that incident, token holders attempted in vain to take over the company’s intellectual property. 

Since that time, Aave Labs has scaled back several side projects and refocused on core lending products. The “Aave Will Win” proposal appears to be part of that reset.

The framework is still only a preliminary signal check for the time being. It would proceed to the official voting stages if there is substantial community support. Future governance decisions and the DAO’s ability to effectively manage a multibillion-dollar brand will determine whether the model proves sustainable.